Intestinal ammonia production

"Intestinal ammonia production" is not a single molecule or receptor but rather a physiological process primarily mediated by the action of intestinal bacteria. These bacteria produce urease, an enzyme that converts urea into ammonia (NH3) and carbon dioxide within the intestinal lumen[1][5][9]. Ammonia is also generated from amino acid deamination during protein breakdown by both host enterocytes and microbial enzymes[1][2][4]. The majority (~50%) of plasma ammonia originates from the intestine, where it is absorbed into the portal circulation and transported to the liver for detoxification via conversion to urea[1][5].\n\nThis process becomes clinically significant in conditions such as hepatic encephalopathy, where impaired hepatic function leads to elevated systemic levels of neurotoxic ammonia[2][5]. Therapeutic strategies target this pathway indirectly—by reducing bacterial populations capable of producing urease (e.g., with antibiotics like rifaximin) or by acidifying colonic contents with nonabsorbable disaccharides like lactulose, which traps ammonium ions in the colon for excretion[1][3].\n\nBecause "intestinal ammonia production" refers to a complex microbial-host metabolic interaction rather than a discrete molecular entity, it should not be classified as a canonical therapeutic target such as an enzyme or receptor. Therefore, this entry is considered incorrect as a molecular target per standard pharmacological conventions.

Other names

Gut ammonia productionIntestinal NH3 generationBacterial urease activity in gutEnteric ammonia formation

Inhibition of bacterial urease (reducing urea-to-ammonia conversion)\nSuppression of gut bacteria producing ammonia (antibiotics)\nAcidification of colonic contents to trap ammonium and reduce absorption (lactulose)